JILGYUNGYI CO.,LTD.
Feminine hygiene company known for its flagship feminine wash brand Jilgyungyi, expanding into digital women's health services.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded 2013, listed on KONEX in 2015, Jilgyungyi is a feminine hygiene company. Flagship product 'Jilgyungyi' is a feminine wash with salt and sugar compounds, sold in tablet, gel/foam, mist, and tissue forms, plus whitening cream, pads, and underwear 'Breeze Fit Square Panty.' It partnered with AI firm Arkril on a women's health app for H2 2026; sales grew from KRW 1.8bn (2014) to KRW 5.8bn (2015).
Products & technology
- JilgyungyiFeminine wash for external cleansing, moisturizing, elasticity and odor care
- 미백크림
- Sanitary pads
- Y존 전용 클렌징 디바이스
- Breeze Fit Square PantyFunctional underwear using natural materials and functional absorption technology, launched in 2025
Regulatory approvals
data.go.kr1 Korean MFDS device approvals · 2021
- MFDSIrrigation unit, vaginal2021-01-07Product approval · Class 2제허 21-11 호
R&D and key agreements
Source: DART corporate disclosureAI 기반 여성 건강관리 APP · 월경, 여성 건강 및 갱년기 관리 등 여성 생애주기별 종합 웰니스케어 · 개발중(2024년 8월 착수, 2026년 하반기 출시 목표) · Developed in partnership with AI firm Arkril, targeting H2 2026 launch
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition